KRAS G12C Mutation: An Emerging Biomarker for NSCLC Sponsored by Amgen®

IE users – if you are experiencing issues trying to register for this webinar, please use Chrome, Safari or Firefox.

Tuesday, December 15, 2020
12:00PM ET/ 9:00 AM PT

Program objectives
At the conclusion of this program, participants will be able to:
Discuss the evolution of biomarkers in NSCLC
Describe KRAS and KRAS G12C prevalence information
Explain diagnostic strategies and options for KRAS G12C testing


Yuri Fesko, MD
Chief Clinical Officer, Oncology Quest Diagnostics
Secaucus, New Jersey


Kari Hooper, MD
Pathologist, AmeriPath®/Quest Diagnostics Department Chair,
Integris Baptist Medical Center Oklahoma City, Oklahoma